Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00305734
- Locations
- 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 79
- Registration Number
- NCT00295932
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2009-02-04
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00291538
- Locations
- 🇫🇷
Lille UH, Lille, France
🇫🇷Nantes UH, Nantes, France
🇫🇷Nancy UH, Nancy, France
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 32
- Registration Number
- NCT00290706
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2018-04-10
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 36
- Registration Number
- NCT00290680
- Locations
- 🇺🇸
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2013-03-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00288041
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT00288028
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2018-03-01
- Target Recruit Count
- 30
- Registration Number
- NCT00287872
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer
- Conditions
- First Posted Date
- 2006-01-20
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00280176
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Bortezomib in Treating Patients With Metastatic Kidney Cancer
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2020-09-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00276614
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.